S33 mutants of beta-catenin aren't phosphorylated

Stable Identifier
R-HSA-5358747
Type
Pathway
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

S33 mutations of beta-catenin interfere with GSK3 phosphorylation and result in stabilization and nuclear localization of the protein and enhanced WNT signaling (Groen et al, 2008; Nhieu et al, 1999; Clements et al, 2002; reviewed in Polakis, 2000). S33 mutations have been identified in cancers of the central nervous system, liver, endometrium and stomach, among others (reviewed in Polakis, 2000).

Literature References
PubMed ID Title Journal Year
10921899 Wnt signaling and cancer

Polakis, P

Genes Dev. 2000
10487827 Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation

Nhieu, JT, Renard, CA, Wei, Y, Cherqui, D, Zafrani, ES, Buendia, MA

Am. J. Pathol. 1999
18757411 Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies

Groen, RW, Oud, ME, Schilder-Tol, EJ, Overdijk, MB, ten Berge, D, Nusse, R, Spaargaren, M, Pals, ST

Cancer Res. 2008
12067995 beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer

Clements, WM, Wang, J, Sarnaik, A, Kim, OJ, MacDonald, J, Fenoglio-Preiser, C, Groden, J, Lowy, AM

Cancer Res. 2002
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cross References
BioModels Database
Authored
Reviewed
Created